Memo Therapeutics Takes A Major Step In High-Throughput Functional Antibody Screening

Creative Commons License Zürich. Source:  Free-Photos , no changes made.
Advertisement img

Memo Therapeutics has announced the development of a droplet sorter that enables functional antibody screening in a high-throughput format.

Founded in 2012, located in the Greater Zürich Area, Switzerland, Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. Exploiting the power of the company’s microfluidic single-cell molecular cloning and screening technologies they engage in antibody discovery across species and indications for proprietary and partnered projects. Their current pipeline features programmes in infectious diseases and immuno-oncology.

This novel microfluidic droplet sorter will be deployed downstream of the MemoMAB antibody repertoire biobanking platform to enable functional screening in a high-throughput format with a series of functional assays such as:

Featured Partners
  • Cell-binding
  • Virus-neutralization
  • Identification of agonistic/antagonistic antibodies
  • Antibody-dependent cellular cytotoxicity (ADCC) assays

“This is a major step in the technology development at Memo since we are now able to directly screen antibody repertoire libraries from rare patients or immunized animals for antibodies with the desired functional activity in a single day.” – Dr. Christoph Esslinger, CSO.

“Having such a tool at hand will enable us to pick the optimal antibody development candidates out of diverse repertoires for our own pipeline and attract high-profile partnerships with pharmaceutical companies.” – Dr. Karsten Fischer, CEO